lmp1/2 ctls
Nasopharyngeal Type Undifferentiated Carcinoma
Explore 1 assets in Nasopharyngeal Type Undifferentiated Carcinoma →Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Catherine Bollard
Modality
Cell therapy
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01956084CT.gov Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma | — | Completed | — | — | — |
NCT00062868CT.gov LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Nasopharyngeal Type Undifferentiated Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| lmp1/2 ctls (this asset) | Catherine Bollard | P1 | CCC · 52 |
| Anti-Egfr Antibody-Drug Conjugate Mrg003 | Sun Yat-sen University | P1 | CC |
| Gefitinib | National Cancer Institute (NCI) | N/A | NR |
Other indications for lmp1/2 ctls
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hodgkins Lymphoma | — | P1 | CCC · 50 |
| Leiomyosarcoma | — | P1 | CCC · 48 |
| Non-Hodgkin Lymphoma | — | P1 | CC · 46 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. lmp1/2 ctls in Nasopharyngeal Type Undifferentiated Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lmp12-ctls-nasopharyngeal-type-undifferentiated-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →